KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price objective reduced by HC Wainwright from $24.00 to $20.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC reiterated a buy rating and set a $35.00 price […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 6.8% on Wednesday . The stock traded as high as $12.13 and last traded at $12.12. Approximately 71,232 shares traded hands during trading, a decline of 90% from the average daily volume of 700,371 shares. The stock had previously closed at $11.35. Wall Street Analysts Forecast […]
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 191.67% from the stock’s […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Leerink Partnrs lowered their Q3 2024 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, February 13th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will post earnings per share of ($0.69) for the quarter, down from […]
By Colin Kellaher KalVista Pharmaceuticals shares surged more than 35% in premarket trading on Tuesday after the clinical-stage pharmaceutical company.